Alpha‐synuclein‐associated changes in PINK1‐PRKN‐mediated mitophagy are disease context dependent

Alpha-synuclein (αsyn) aggregates are pathological features of several neurodegenerative conditions including Parkinson disease (PD), dementia with Lewy bodies, and multiple system atrophy (MSA). Accumulating evidence suggests that mitochondrial dysfunction and impairments of the autophagic-lysosomal system can contribute to the deposition of αsyn, which in turn may interfere with health and function of these organelles in a potentially vicious cycle. Here we investigated a potential convergence of αsyn with the PINK1-PRKN-mediated mitochondrial autophagy pathway in cell models, αsyn transgenic mice, and human autopsy brain. PINK1 and PRKN identify and selectively label damaged mitochondria with phosphorylated ubiquitin (pS65-Ub) to mark them for degradation (mitophagy). We found that disease-causing multiplications of αsyn resulted in accumulation of the ubiquitin ligase PRKN in cells. This effect could be normalized by starvation-induced autophagy activation and by CRISPR/Cas9-mediated αsyn knockout. Upon acute mitochondrial damage, the increased levels of PRKN protein contributed to an enhanced pS65-Ub response. We further confirmed increased pS65-Ub-immunopositive signals in mouse brain with αsyn overexpression and in postmortem human disease brain. Of note, increased pS65-Ub was associated with neuronal Lewy body-type αsyn pathology, but not glial cytoplasmic inclusions of αsyn as seen in MSA. While our results add another layer of complexity to the crosstalk between αsyn and the PINK1-PRKN pathway, distinct mechanisms may underlie in cells and brain tissue despite similar outcomes. Notwithstanding, our finding suggests that pS65-Ub may be useful as a biomarker to discriminate different synucleinopathies and may serve as a potential therapeutic target for Lewy body disease.

[1]  D. Klenerman,et al.  Pathological structural conversion of α-synuclein at the mitochondria induces neuronal toxicity , 2022, Nature Neuroscience.

[2]  S. K. Barodia,et al.  Analysis of hemisphere-dependent effects of unilateral intrastriatal injection of α-synuclein pre-formed fibrils on mitochondrial protein levels, dynamics, and function , 2022, Acta neuropathologica communications.

[3]  I. McKeith,et al.  α-Synuclein phosphorylation at serine 129 occurs after initial protein deposition and inhibits seeded fibril formation and toxicity , 2022, Proceedings of the National Academy of Sciences of the United States of America.

[4]  D. Dickson,et al.  Neuropathology and molecular diagnosis of Synucleinopathies , 2021, Molecular Neurodegeneration.

[5]  S. Gunawardena,et al.  Differential mitochondrial roles for α-synuclein in DRP1-dependent fission and PINK1/Parkin-mediated oxidation , 2021, Cell Death & Disease.

[6]  D. Dickson,et al.  Deep learning‐based model for diagnosing Alzheimer's disease and tauopathies , 2021, Neuropathology and applied neurobiology.

[7]  T. Kunath,et al.  Midbrain organoids with an SNCA gene triplication model key features of synucleinopathy , 2021, bioRxiv.

[8]  M. Feany,et al.  α-synuclein impairs autophagosome maturation through abnormal actin stabilization , 2021, PLoS genetics.

[9]  M. Meyer,et al.  Interaction between Parkin and α-Synuclein in PARK2-Mediated Parkinson’s Disease , 2021, Cells.

[10]  I. McKeith,et al.  Lipids, lysosomes and mitochondria: insights into Lewy body formation from rare monogenic disorders , 2021, Acta Neuropathologica.

[11]  D. Dickson,et al.  Sensitive ELISA-based detection method for the mitophagy marker p-S65-Ub in human cells, autopsy brain, and blood samples , 2020, Autophagy.

[12]  L. Petrucelli,et al.  Mitophagy alterations in Alzheimer's disease are associated with granulovacuolar degeneration and early tau pathology , 2020, Alzheimer's & dementia : the journal of the Alzheimer's Association.

[13]  V. Baekelandt,et al.  The structural differences between patient-derived α-synuclein strains dictate characteristics of Parkinson’s disease, multiple system atrophy and dementia with Lewy bodies , 2020, Acta Neuropathologica.

[14]  H. Ruley,et al.  Intracellular delivery of Parkin rescues neurons from accumulation of damaged mitochondria and pathological α-synuclein , 2020, Science Advances.

[15]  M. Goldberg,et al.  Enhanced Susceptibility of PINK1 Knockout Rats to α-Synuclein Fibrils , 2020, Neuroscience.

[16]  G. Knott,et al.  The process of Lewy body formation, rather than simply α-synuclein fibrillization, is one of the major drivers of neurodegeneration , 2020, Proceedings of the National Academy of Sciences.

[17]  F. Fiesel,et al.  Autophagy in Parkinson's disease. , 2020, Journal of molecular biology.

[18]  M. Tagliati,et al.  iPSC modeling of young-onset Parkinson’s disease reveals a molecular signature of disease and novel therapeutic candidates , 2020, Nature Medicine.

[19]  D. Selkoe,et al.  Parkinson’s disease: proteinopathy or lipidopathy? , 2020, npj Parkinson's Disease.

[20]  D. Klenerman,et al.  Analysis of α-synuclein species enriched from cerebral cortex of humans with sporadic dementia with Lewy bodies , 2020, Brain communications.

[21]  J. Kordower,et al.  Endogenous alpha-synuclein monomers, oligomers and resulting pathology: let’s talk about the lipids in the room , 2019, npj Parkinson's Disease.

[22]  G. Monzio Compagnoni,et al.  Understanding the pathogenesis of multiple system atrophy: state of the art and future perspectives , 2019, Acta neuropathologica communications.

[23]  W. V. van IJcken,et al.  Lewy pathology in Parkinson’s disease consists of crowded organelles and lipid membranes , 2019, Nature Neuroscience.

[24]  A. Lieberman,et al.  Pathogenic alpha-synuclein aggregates preferentially bind to mitochondria and affect cellular respiration , 2019, Acta neuropathologica communications.

[25]  M. Goldberg,et al.  Analysis of α-Synuclein Pathology in PINK1 Knockout Rat Brains , 2019, Front. Neurosci..

[26]  M. Farrer,et al.  Age- and disease-dependent increase of the mitophagy marker phospho-ubiquitin in normal aging and Lewy body disease , 2018, Autophagy.

[27]  P. McLean,et al.  Alpha-synuclein-induced mitochondrial dysfunction is mediated via a sirtuin 3-dependent pathway , 2018, bioRxiv.

[28]  Xinnan Wang,et al.  Alpha-synuclein delays mitophagy and targeting Miro rescues neuron loss in Parkinson’s models , 2018, Acta Neuropathologica.

[29]  John L. Robinson,et al.  Cellular Milieu Imparts Distinct Pathological α-Synuclein Strains in α-Synucleinopathies , 2018, Nature.

[30]  N. Kamasawa,et al.  Identification of a highly neurotoxic α-synuclein species inducing mitochondrial damage and mitophagy in Parkinson’s disease , 2018, Proceedings of the National Academy of Sciences.

[31]  M. Feany,et al.  α-synuclein Induces Mitochondrial Dysfunction through Spectrin and the Actin Cytoskeleton , 2018, Neuron.

[32]  D. Galasko,et al.  Autophagy inhibition promotes SNCA/alpha-synuclein release and transfer via extracellular vesicles with a hybrid autophagosome-exosome-like phenotype , 2018, Autophagy.

[33]  Federico N. Soria,et al.  Mitochondrial division inhibitor-1 is neuroprotective in the A53T-α-synuclein rat model of Parkinson’s disease , 2017, Scientific Reports.

[34]  Michael J. Devine,et al.  α-Synuclein binds to the ER–mitochondria tethering protein VAPB to disrupt Ca2+ homeostasis and mitochondrial ATP production , 2017, Acta Neuropathologica.

[35]  T. Caulfield,et al.  PINK1, Parkin, and Mitochondrial Quality Control: What can we Learn about Parkinson’s Disease Pathobiology? , 2016, Journal of Parkinson's disease.

[36]  A. Mrejeru,et al.  Parkin and PINK1 Patient iPSC-Derived Midbrain Dopamine Neurons Exhibit Mitochondrial Dysfunction and α-Synuclein Accumulation , 2016, Stem cell reports.

[37]  Caitlyn W. Barrett,et al.  α-Synuclein binds to TOM20 and inhibits mitochondrial protein import in Parkinson’s disease , 2016, Science Translational Medicine.

[38]  P. Calabresi,et al.  Lysosomal Dysfunction and α‐Synuclein Aggregation in Parkinson's Disease: Diagnostic Links , 2016, Movement disorders : official journal of the Movement Disorder Society.

[39]  M. Xilouri,et al.  Autophagy and Alpha‐Synuclein: Relevance to Parkinson's Disease and Related Synucleopathies , 2016, Movement disorders : official journal of the Movement Disorder Society.

[40]  D. Dickson,et al.  Autosomal dominant Parkinson's disease caused by SNCA duplications. , 2016, Parkinsonism & related disorders.

[41]  Takeo Kato,et al.  Sensitive western blotting for detection of endogenous Ser129-phosphorylated α-synuclein in intracellular and extracellular spaces , 2015, Scientific Reports.

[42]  Elisabeth L. Moussaud-Lamodière,et al.  (Patho‐)physiological relevance of PINK1‐dependent ubiquitin phosphorylation , 2015, EMBO reports.

[43]  M. Giugliano,et al.  α-Synuclein strains cause distinct synucleinopathies after local and systemic administration , 2015, Nature.

[44]  P. McLean,et al.  Targeting α-synuclein oligomers by protein-fragment complementation for drug discovery in synucleinopathies , 2015, Expert opinion on therapeutic targets.

[45]  K. Lim,et al.  Convergence of Parkin, PINK1, and α-Synuclein on Stress-induced Mitochondrial Morphological Remodeling* , 2015, The Journal of Biological Chemistry.

[46]  Richard Wade-Martins,et al.  Mitochondrial dysfunction and mitophagy in Parkinson's: from familial to sporadic disease. , 2015, Trends in biochemical sciences.

[47]  X. Zhuang,et al.  A53T Human α-Synuclein Overexpression in Transgenic Mice Induces Pervasive Mitochondria Macroautophagy Defects Preceding Dopamine Neuron Degeneration , 2015, The Journal of Neuroscience.

[48]  J. Roeper,et al.  Potentiation of neurotoxicity in double-mutant mice with Pink1 ablation and A53T-SNCA overexpression , 2014, Human molecular genetics.

[49]  V. Baekelandt,et al.  Alpha-synuclein-induced neurodegeneration is exacerbated in PINK1 knockout mice , 2014, Neurobiology of Aging.

[50]  C. Páyan-Gomez,et al.  Bioenergetic and proteolytic defects in fibroblasts from patients with sporadic Parkinson's disease. , 2014, Biochimica et biophysica acta.

[51]  G. Halliday,et al.  α-Synucleinopathy phenotypes. , 2014, Parkinsonism & related disorders.

[52]  D. Dickson,et al.  Diversity of pathological features other than Lewy bodies in familial Parkinson's disease due to SNCA mutations. , 2013, American journal of neurodegenerative disease.

[53]  Ssang-Goo Cho,et al.  Autophagic failure promotes the exocytosis and intercellular transfer of α-synuclein , 2013, Experimental & Molecular Medicine.

[54]  Y. Tohyama,et al.  Tubulin Polymerization-promoting Protein (TPPP/p25α) Promotes Unconventional Secretion of α-Synuclein through Exophagy by Impairing Autophagosome-Lysosome Fusion* , 2013, The Journal of Biological Chemistry.

[55]  Yi Zhang,et al.  Direct Conversion of Fibroblasts to Neurons by Reprogramming PTB-Regulated MicroRNA Circuits , 2013, Cell.

[56]  M. Xilouri,et al.  Alpha-synuclein and Protein Degradation Systems: a Reciprocal Relationship , 2013, Molecular Neurobiology.

[57]  H. Okano,et al.  Mitochondrial dysfunction associated with increased oxidative stress and α-synuclein accumulation in PARK2 iPSC-derived neurons and postmortem brain tissue , 2012, Molecular Brain.

[58]  Patrick A. Lewis,et al.  Parkinson's disease induced pluripotent stem cells with triplication of the α-synuclein locus , 2011, Nature communications.

[59]  T. Kamitani,et al.  Improved Immunodetection of Endogenous α-Synuclein , 2011, PloS one.

[60]  R. Nussbaum,et al.  Direct Membrane Association Drives Mitochondrial Fission by the Parkinson Disease-associated Protein α-Synuclein*♦ , 2011, The Journal of Biological Chemistry.

[61]  V. Choubey,et al.  Mutant A53T α-Synuclein Induces Neuronal Death by Increasing Mitochondrial Autophagy* , 2011, The Journal of Biological Chemistry.

[62]  C. Oliveira,et al.  Mitochondrial Dysfunction: The Road to Alpha-Synuclein Oligomerization in PD , 2011, Parkinson's disease.

[63]  Thomas Gasser,et al.  Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria , 2009, The Lancet Neurology.

[64]  John Hardy,et al.  Parkinson's disease , 2009, The Lancet.

[65]  B. E. Staveley,et al.  Pink1 suppresses alpha-synuclein-induced phenotypes in a Drosophila model of Parkinson's disease. , 2008, Genome.

[66]  V. Bader,et al.  Mono- and double-mutant mouse models of Parkinson's disease display severe mitochondrial damage. , 2007, Human molecular genetics.

[67]  S. Miyachi,et al.  Neuronal specificity of α-synuclein toxicity and effect of Parkin co-expression in primates , 2007, Neuroscience.

[68]  D. Price,et al.  Parkinson's Disease α-Synuclein Transgenic Mice Develop Neuronal Mitochondrial Degeneration and Cell Death , 2006, The Journal of Neuroscience.

[69]  C. Ross,et al.  Parkin Mediates Nonclassical, Proteasomal-Independent Ubiquitination of Synphilin-1: Implications for Lewy Body Formation , 2005, The Journal of Neuroscience.

[70]  T. Iwatsubo,et al.  Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an alpha-synuclein rat model of Parkinson's disease. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[71]  B. Hyman,et al.  Parkin localizes to the Lewy bodies of Parkinson disease and dementia with Lewy bodies. , 2002, The American journal of pathology.

[72]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[73]  C. Ross,et al.  Parkin ubiquitinates the α-synuclein–interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease , 2001, Nature Medicine.

[74]  M. Farrer,et al.  Distinctive neuropathology revealed by α-synuclein antibodies in hereditary parkinsonism and dementia linked to chromosome 4p , 2000, Acta Neuropathologica.

[75]  L. Mucke,et al.  Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. , 2000, Science.